EC Grants Orphan Drug Designation to Pharming’s Leniolisib

Article

EC has granted orphan drug designation to Pharming Group for its treatment of activated phosphoinositide 3-kinase delta syndrome, leniolisib.

The European Commission (EC) has granted orphan drug designation to Pharming Group for its treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), leniolisib, based on the positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).

“We are pleased to have received orphan drug designation from the EC, an important milestone in the development of leniolisib for the treatment for APDS, an ultra-rare and debilitating disease,” said Sijmen de Vries, CEO of Pharming, in an Oct. 21, 2020 press release. “With no currently approved treatment, leniolisib has the potential to address a significant unmet need for patients with APDS. Leniolisib is currently being studied in a registration-enabling Phase II/III trial and remains, subject to regulatory approval, on track to launch in H2 2022.”

Leniolisib is a small molecule phosphoinositide 3-kinase delta inhibitor with immunomodulating and potentially anti-neoplastic activities. It has been granted orphan drug designation by the US Food and Drug Administration in January 2018 for the treatment of APDS or p110δ-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency.

Source: Pharming

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes